Current therapy of primary systemic (AL) amyloidosis with oral melphalan and prednisone remains unsatisfactory, with a median survival of only 13 months. Between 1996 and 2003, 93 patients with biopsy proven AL amyloidosis were enrolled in a prospective US national cooperative group trial. Treatment schema consisted of induction therapy with pulse dexamethasone (DEX), followed by maintenance therapy with DEX and alpha interferon. Hematologic complete remissions were observed in 24% and improvement in AL related organ dysfunction occurred in 45% of patients evaluable for response. Median survival of the entire cohort is 31 months, with an estimated 2 year overall (OS) and event free survival (EFS) of 60% and 52% respectively. Presence of congestive heart failure and increased level of serum beta 2 microglobulin (> 3.5 mg/L) were dominant predictors of adverse outcome. Estimated 2 year OS in transplant eligible patients with this approach was 78%. These data demonstrate for the first time in the context of a US multicenter prospective clinical trial, that front line therapy with a DEX based regimen in AL amyloidosis can lead to durable reversal of AL related organ dysfunction, and prolonged survival.
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Background:
Primary (AL) amyloidosis, the most common systemic amyloidosis in the United States (US), is a clonal plasma cell disorder characterized by the deposition of a congophilic beta pleated fibrillary protein containing monoclonal light chain fragments in affected organs 1,2 . The pattern of organ involvement varies among individuals and determines clinical presentation. The prognosis of systemic AL is generally poor with a median survival of 12-18 months. Current standard therapy with oral melphalan and prednisone (MP) yields clinical responses in only 20-25% of patients, which occur slowly at a median time of 12 months 3 . Thus prolonged alkylator therapy is required, contributing to increased risk of myelodysplasia / leukemia (estimated actuarial risk 21% at 3.5 years) 4 .
In 1997, Dhodapkar et al. first described the clinical activity of high dose dexamethasone (DEX) in AL amyloidosis, testing the hypothesis that more aggressive anti-plasma cell approaches, analogous to those in myeloma, might lead to improved outcome in this disease 5 . Clinical activity of DEX or DEX based regimens in AL amyloid has since been confirmed by other investigators as well [6] [7] [8] [9] [10] . However, most of the current data regarding therapy for AL amyloidosis are based on single institution studies, raising unresolved issues related to referral and patient selection bias 11, 12 . Therefore South West Oncology Group (SWOG) initiated a prospective multi-center clinical trial to evaluate the clinical efficacy of DEX / alpha interferon in patients with systemic AL amyloidosis. In this paper,
we describe the results of this first large prospective US national cooperative group effort in patients with systemic AL amyloidosis.
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Methods:
Study Design and Eligibility Criteria:
Study design consisted of sequential registration to induction followed by maintenance therapy. Patients with histologic diagnosis of AL amyloidosis and evidence of tissue involvement other than carpal tunnel syndrome were registered in this trial. Other eligibility criteria included SWOG performance status (PS) score of 0-3, and no prior therapy with DEX and alpha interferon. Patients with PS score of 4 were eligible if solely due to peripheral or autonomic neuropathy. Exclusion criteria were overt multiple myeloma, uncontrolled diabetes, active peptic ulcer disease, New York Heart Association Class IV congestive heart failure (CHF), prior malignancy, pregnant or nursing women.
All diagnostic material was subjected to central pathology review. All patients signed informed consent approved by the local institutional review board, prior to study entry.
Laboratory and Clinical Monitoring:
Baseline evaluation prior to each registration included a complete physical examination, serum and urine immunofixation electrophoresis, serum beta 2 microglobulin, assessment of liver and renal function, electrocardiogram, echocardiography, bone marrow aspiration and biopsy, abdominal fat aspirate and skeletal survey. Other studies to assess organ involvement depended on clinical presentation. These included computed tomography (CT) or ultrasound of the abdomen in patients with liver involvement; electromyography week for the first 2 years, followed by alpha interferon alone for the next 3 years. In patients unable to tolerate interferon, dexamethasone alone was used in the maintenance phase at 40 mg/day for 4 days every 4 weeks for 2 years, followed by 20 mg/day for 4 days every 2 months for years 3-5. In the event of grade 3 or persistent (> 1 month) grade 2 toxicity during any phase of therapy, the offending agent was temporarily withheld until resolution of toxicity to grade 1 or better, and then resumed at 50% of the original dose.
Response Assessment:
Response to therapy and disease progression was assessed separately for both hematologic response and improvement in organ dysfunction, based on SWOG and Mayo Clinic criteria, respectively 13 . Briefly, cardiac response required both improvement in cardiac Improvement in performance status alone was not considered adequate for organ response, as it may also be due to improved supportive care.
Statistical Analysis:
Overall survival (OS) was calculated as time from registration to the date of last contact or date of death. Disease progression was assessed as previously described 5 . Progression free survival (PFS) was calculated as time from registration to the date of progression, death or last contact. Survival curves were estimated by using the product limit method 14 and compared using the log rank test 15 . Proportions were compared using the chi square test.
Univariate and multivariate analyses were done using the Cox regression model for survival 16 , and logistic regression for binary endpoints 17 . Independently significant variables in the multivariate analyses were selected using backward selection at the 0.05 level with results confirmed using forward selection at the 0.05 level.
Potential prognostic factors were examined primarily as dichotomous groups, as the goal was to utilize easily interpreted groupings. Recursive partitioning methods were used to calculate the best cut point (based on the log rank statistic) for continuous variables 18 .
Recursive partitioning methods are based on the raw data and compute cut points that provide the greatest separation in the outcome of interest, in this case overall survival.
Groups defined by the optimal cut point were restricted to contain a minimum of 20% of the evaluable patients. Permutation adjusted log rank tests were performed to estimate the For personal use only. on January 15, 2018. by guest www.bloodjournal.org From significance on overall survival of recursively selected cut points 19 .
Results:
Accrual:
Between November 1996 and March 2003, 93 patients were registered to this clinical trial.
Five patients were excluded due to failure to meet eligibility requirements. One patient withdrew informed consent before receiving any protocol treatment. This analysis is restricted to the remaining 87 eligible and analyzable patients. Feasibility of national cooperative group studies in AL amyloidosis in the US was a major objective in this trial.
A total of 25 SWOG institutions and 9 CALGB institutions participated in this trial, with 32 institutions contributing < 5 patients, which constituted 59% of the total accrual.
Therefore these data illustrate the feasibility of national cooperative group effort for accruing patients with this relatively uncommon disorder.
Clinical Characteristics:
Clinical characteristics of this cohort are shown in Table 1 . Median age of all patients was 67.1 years. Most patients were previously untreated, although 14 (16%) patients had previously received oral melphalan and prednisone. Most patients (71%) had multi-organ involvement, with > 3 organ involvement in 36%. The most commonly involved organs were renal (74%) and cardiac (50%). Of 81 patients with information regarding the date of initial pathologic diagnosis, 62 (77%) patients were diagnosed within 90 days prior to enrollment.
Response to therapy: Improvement in AL related organ dysfunction (termed organ response) was a major end point in this trial, and was assessed separately for each involved organ, as in other amyloid trials. Organ response in at least one involved organ was seen in 33 (45%) of 73 patients evaluable for organ response ( Table 2) . Frequency of the organ response depended on the nature of the involved organ / system, and was the highest for patients with renal involvement (39%), and lowest for patients with neuropathy (3%). Hematologic response to therapy (> partial response) occurred in 53% of 55 patients evaluable for hematologic response, with complete remissions (CR) in 24%. Improvement in organ function correlated with hematologic response to therapy (data not shown). Figure 1 shows the cumulative incidence of hematologic and organ response over the first year of therapy in the cohort assessable for both responses. The median time to hematologic PR or better was 103 days, and the median time to CR was 173 days. Median time to organ response is 120 days. A proportion of patients were taken off study by the treating physician to pursue other therapies such as high dose melphalan/stem cell transplantation (n=4); thalidomide (n=3) or vaccines (n=1). Data for response to these therapies is not available. (11, 31) The estimated 2 and 5 year OS in the entire cohort is 60% and 28% respectively. The median time to disease progression in the entire cohort is 27 months, with 2 and 5 year progression free survival (PFS) of 52% and 18% respectively ( Figure 2B Figure 3A and 3B). Majority of patients enrolled in this trial had advanced amyloid. Only 23 of these patients met the criteria generally utilized for eligibility for high dose chemotherapy and stem cell transplantation in this disease (age < 70 years old, without CHF, < 3 organ involvement, and serum creatinine of < 2 mg/dl). Estimated 2 year OS in this cohort was 78% compared to 56% in patients known to be transplant ineligible (p=0.006, Figure 4 ). 
Toxicities
Pulse DEX administered at full dose (40 mg/d) has an acceptable toxicity profile in patients with myeloma, however the tolerance to this regimen in patients with AL amyloid seems to be lower. Major treatment related > grade 3 toxicities during the induction or maintenance phase are noted in Table 3 . Treatment related mortality was observed in 6 (7%) patients. This included 4 patients with advanced cardiac amyloid who experienced sudden death, likely due to a cardiac event. Overall, the incidence of grade 3 or greater toxicities during the induction or maintenance phase was 51% and 67% respectively. However, these toxicities generally occurred early during the initiation of therapy, and responded well to dose reduction in most instances. Fifty eight (67%) patients received at least 3 cycles of induction therapy. The most common toxicity during induction therapy was cardiovascular / fluid overload related to dexamethasone, in 28 % of patients. The most common toxicity during the maintenance phase was neurologic in 24% of patients, which included neuropsychiatric manifestations and depression possibly related to alpha interferon. Four patients could not tolerate interferon and were maintained on dexamethasone alone. Median duration of follow up on maintenance therapy was 214 days For personal use only. on January 15, 2018. by guest www.bloodjournal.org From and 11 patients had a follow up of > 2 years on maintenance therapy. In univariate analysis, patient characteristics significantly associated with higher risk of grade 4 or greater toxicity were the presence of > 2 organ/systems involved and GI involvement, while the presence of CHF and serum 2 microglobulin ( 2m) > 3.5 mg/L approached significance (data not shown). On multivariate analysis, only the presence of CHF (odds ratio 5.8, p=0.01) remained as a significant variable, while serum 2m > 3.5 mg/L (odds ratio 3.8, p=0.08) approached significance.
Prognostic factors for survival
Results of univariate analysis for predictors of OS and PFS in this study are shown in Table 4 . Significant univariate prognostic factors for adverse outcome at the 0.05 level were age > 65 years, performance status score > 1, > 2 organ / systems involved, congestive heart failure, and neurologic involvement, while serum 2m and urine M approached significance. In the multivariate model, only the presence of congestive heart failure and serum levels of 2m were significant independent predictors of both OS and PFS (Table 5) . Utilizing these two variables, we developed a risk model for predicting outcome in this disease, based on the presence of none, one or both of these risk features. 2 year overall survival in these cohorts was 77%, 66% and 0% months respectively ( Figure   5 ; p < 0.001).
For personal use only. on January 15, 2018. by guest www.bloodjournal.org From Figure 5 . Disease risk model based on the presence of congestive heart failure and serum beta 2 microglobulin. High B2M is defined as serum beta 2 microblobulin at least 3.5 mg/L.
Discussion:
AL amyloidosis is a rapidly fatal disease with only modest impact of current therapies 1 .
Most of the current data regarding therapy of these patients is based on single institution studies from major amyloid treatment centers. However, these studies also suggest an important impact of patient selection on outcome 11 . [6] [7] [8] . In these studies, the overall response to DEX was variable, and the impact on survival difficult to assess. Differences in response rates in these studies may be due to small sample sizes, differences in patient populations or treatment regimens, including lack of maintenance phase, or alpha interferon. Alpha interferon as a single agent does not seem to have significant activity in this disease 20 , but the potential for synergy with DEX can not be excluded. Recent studies have also explored the combination of DEX with vincristine/adriamycin (as in the VAD regimen) 9 and with melphalan 10 . However, it remains unclear whether the addition of these agents to DEX will lead to improved outcome compared to DEX alone. Nonetheless, cumulative results from these studies (including the present study) support the consideration of DEX or DEX based regimens as one of the options for front-line therapy in AL amyloidosis. In view of the activity of combinations of DEX with thalidomide or proteasome inhibitors in myeloma, formal evaluation of these regimens in AL amyloidosis is warranted.
In this study, different organ / systems had differing propensity to respond to this regimen.
For example, organ responses rates were highest among patients with renal involvement, while only one of the 31 patients with neuropathies had an objective response. Higher rates of response in neuropathies have been reported after high dose melphalan 21 , although response criteria in some of these studies did not include objective evidence of improvement on serial EMG testing, as required here. Nonetheless, pattern of organ involvement may be worthy of consideration when choosing initial therapy in patients with AL amyloidosis. Improvement in organ function however does not necessarily mean regression of amyloid deposits. This issue was not addressed in this trial as follow up biopsies of involved organ were not performed. Improvement in organ function correlated
For personal use only. on January 15, 2018. by guest www.bloodjournal.org From with improved survival. Surprisingly, similar association could not be demonstrated for hematologic response, suggesting that organ improvement is a stronger predictor of survival. Hematologic response to therapy did however correlate with organ responses.
Measurement of serum free light chains was not commercially available when this study was initiated, and might have improved the assessment of hematologic responses.
Both DEX and alpha interferon have an acceptable toxicity profile in patients with myeloma, but the tolerance to both these agents in patients with AL amyloidosis seems to be lower. In this study, nearly half of the patients required dose reduction early in the induction phase due to dose limiting toxicities. This occurred in spite of using a lower starting dose (20 mg) in older patients. Intolerance to maintenance DEX-interferon was also higher than would be expected and again required dose reduction, particularly for interferon. Therefore based on these data, we recommend that the use of DEX in AL should be individualized, starting with a lower dose such as 20 mg. Patients with CHF appear to be at higher risk of toxicity, without survival benefit and therefore should not be treated with such regimens.
Another approach with promising results in selected patients is the use of high dose or risk adapted melphalan with autologous stem cell transplantation (ASCT) 21, 22 . However, the degree to which the current results with ASCT in AL amyloid are influenced by patient selection factors remains unclear. In this trial, the survival of the cohort eligible for ASCT is comparable to the data from single institution ASCT trials 21 . These data therefore underscore the need to compare this approach in a randomized trial to DEX based therapies, to avoid repeating the lessons learnt with ASCT in breast cancer 23 . Perhaps more importantly, only a minority of patients in this trial would have met the eligibility of published transplant trials. Therefore, there is a great need to identify newer approaches to benefit this population.
Presence of CHF and high serum 2m were the dominant prognostic indicators in this study. Prognostic impact of symptomatic cardiac involvement in AL is well established.
Although not tested in this trial, it is likely that more objective measures of cardiac involvement such as troponin levels or levels of brain natriuretic peptide, along with serum 2m will help identify risk groups in this disease 24 . Adverse impact of high serum 2m in AL amyloid was also noted earlier by the Mayo Clinic group 25 . Level of serum 2m is also a dominant prognostic factor in myeloma, where it is generally considered to be indicative of high clonal tumor burden. Therefore we find its prognostic impact in AL amyloidosis intriguing because these patients characteristically have much lower clonal burden relative to myeloma. Patients with both these risk features did very poorly in this trial, and should not be treated with DEX. Unfortunately, these patients are also likely to do poorly with other approaches, and may be candidates for trials testing novel agents.
In conclusion, these data provide evidence for clinical activity of a novel approach to treat patients with AL amyloidosis, and consideration of DEX based regimens as an option for front line therapy in AL amyloidosis, particularly when more rapid response is desirable. Prognostic factors considered but not significant after adjusting for CHF and 2M>=3.5 mg/L are age>=65(yrs), gender, performance status>1, serum creatinine >=2.0mg/dL, serum albumin <3.5g/dL, serum alkaline phosphatase > upper limit normal, and number of organ systems involved (>2).
